JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Certara Inc

Fermé

SecteurSoins de santé

7.22 -2.04

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.19

Max

7.37

Chiffres clés

By Trading Economics

Revenu

3.5M

1.5M

Ventes

46K

105M

P/E

Moyenne du Secteur

118.571

84.243

Marge bénéficiaire

1.458

Employés

1,487

EBITDA

-6.5M

23M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+60.03% upside

Dividendes

By Dow Jones

Prochains Résultats

26 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-557M

1.3B

Ouverture précédente

9.26

Clôture précédente

7.22

Sentiment de l'Actualité

By Acuity

50%

50%

139 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Certara Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 févr. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 févr. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 févr. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 févr. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 févr. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 févr. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 févr. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 févr. 2026, 02:46 UTC

Acquisitions, Fusions, Rachats

Big Money, High Anxiety -- Barrons.com

6 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 févr. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6 févr. 2026, 21:40 UTC

Acquisitions, Fusions, Rachats

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 févr. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 févr. 2026, 21:17 UTC

Résultats

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 févr. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 févr. 2026, 21:14 UTC

Acquisitions, Fusions, Rachats

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 févr. 2026, 21:13 UTC

Résultats

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 févr. 2026, 21:13 UTC

Résultats

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 févr. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 févr. 2026, 20:34 UTC

Résultats

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Comparaison

Variation de prix

Certara Inc prévision

Objectif de Prix

By TipRanks

60.03% hausse

Prévisions sur 12 Mois

Moyen 11.57 USD  60.03%

Haut 13 USD

Bas 9 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

9 ratings

6

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

11.27 / 12.79Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

139 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat